Is HCA Healthcare, Inc. overvalued or undervalued?

As of 20 July 2021, HCA Healthcare, Inc. has moved from an expensive to a risky valuation grade. The company is currently considered undervalued. Key ratios include a P/E ratio of 14, an EV to EBITDA of 9.56, and a PEG ratio of 1.15, which suggest that the stock may be trading at a discount relative to its earnings growth potential.
In comparison to peers, HCA Healthcare's P/E ratio of 13.41 and EV to EBITDA of 9.35 indicate that it is positioned favorably against its industry. Notably, the company has a high ROCE of 27.18%, which further supports its valuation. Recent stock performance shows that HCA has outperformed the S&P 500 year-to-date, with a return of 26.18% compared to the index's 2.44%, reinforcing the notion that the stock may be undervalued.